advertisement

Oculus

11.3.4 Betablocker (19)

Showing records 1 to 19

Display all abstracts in classification 11.3.4 Betablocker

Search within classification 11.3.4 Betablocker
82426 New technique to reduce systemic side effects of timolol eye drops: The tissue press method-Cross-over clinical trial
Müller L
Clinical and Experimental Ophthalmology 2020; 48: 24-30
82317 Neuropsychiatric Adverse Events from Topical Ophthalmic Timolol
Cimolai N
Clinical medicine & research 2019; 17: 90-96
82654 Autoantibodies Activating the β2-Adrenergic Receptor Characterize Patients With Primary and Secondary Glaucoma
Hohberger B
Frontiers in immunology 2019; 10: 2112
82361 Psoriasis precipitated by timolol eye drops. A series of eight cases
Mir-Bonafé JF; Rozas-Muñoz E
Australasian Journal of Dermatology 2020; 61: e91-e93
82654 Autoantibodies Activating the β2-Adrenergic Receptor Characterize Patients With Primary and Secondary Glaucoma
Kunze R
Frontiers in immunology 2019; 10: 2112
82426 New technique to reduce systemic side effects of timolol eye drops: The tissue press method-Cross-over clinical trial
Jensen BP
Clinical and Experimental Ophthalmology 2020; 48: 24-30
82361 Psoriasis precipitated by timolol eye drops. A series of eight cases
Pedemonte-Sarrias E
Australasian Journal of Dermatology 2020; 61: e91-e93
82654 Autoantibodies Activating the β2-Adrenergic Receptor Characterize Patients With Primary and Secondary Glaucoma
Wallukat G
Frontiers in immunology 2019; 10: 2112
82426 New technique to reduce systemic side effects of timolol eye drops: The tissue press method-Cross-over clinical trial
Bachmann LM
Clinical and Experimental Ophthalmology 2020; 48: 24-30
82361 Psoriasis precipitated by timolol eye drops. A series of eight cases
Mir-Bonafé M
Australasian Journal of Dermatology 2020; 61: e91-e93
82426 New technique to reduce systemic side effects of timolol eye drops: The tissue press method-Cross-over clinical trial
Wong D
Clinical and Experimental Ophthalmology 2020; 48: 24-30
82654 Autoantibodies Activating the β2-Adrenergic Receptor Characterize Patients With Primary and Secondary Glaucoma
Kara K; Mardin CY
Frontiers in immunology 2019; 10: 2112
82361 Psoriasis precipitated by timolol eye drops. A series of eight cases
Mir-Bonafé JM
Australasian Journal of Dermatology 2020; 61: e91-e93
82426 New technique to reduce systemic side effects of timolol eye drops: The tissue press method-Cross-over clinical trial
Wells AP
Clinical and Experimental Ophthalmology 2020; 48: 24-30
82654 Autoantibodies Activating the β2-Adrenergic Receptor Characterize Patients With Primary and Secondary Glaucoma
Lämmer R
Frontiers in immunology 2019; 10: 2112
82361 Psoriasis precipitated by timolol eye drops. A series of eight cases
Piquero-Casals J
Australasian Journal of Dermatology 2020; 61: e91-e93
82654 Autoantibodies Activating the β2-Adrenergic Receptor Characterize Patients With Primary and Secondary Glaucoma
Schlötzer-Schrehardt U
Frontiers in immunology 2019; 10: 2112
82361 Psoriasis precipitated by timolol eye drops. A series of eight cases
Puig L
Australasian Journal of Dermatology 2020; 61: e91-e93
82654 Autoantibodies Activating the β2-Adrenergic Receptor Characterize Patients With Primary and Secondary Glaucoma
Hosari S; Hosari S; Horn F; Munoz L; Herrmann M
Frontiers in immunology 2019; 10: 2112

Issue 20-4

Select Issue


advertisement

WGC-2021